EBX-002 for Non-Tuberculous Mycobacterial Lung Infections
Relapse of NTM Infection is Common and Eradication Difficult:
- NTM is a chronic, debilitating disease generating significant morbidity and mortality
- NTM more prevalent than TB in the US
- Highest incidence growth among patients aged 65+, a population expected to double by 2030
EBX-002 for NTM Treatment:
EBX-002 is a combination of amikacin (AMK) and a potentiator molecule (PTN) expected to be a superior treatment for persistent NTM infections versus amikacin alone.
EBX-002 significantly enhances killing of bacterial persisters through a novel proton-motive-force (PMF) enhancing mechanism. Data collected in collaboration with Luiz Bermudez at Oregon State University, a pioneer in mycobacterial pathogenetic mechanisms, show >4 logs of enhanced killing of M. avium persisters with EBX-002 versus AMK alone.
Superiority over AMK, including liposomal formulations, is anticipated.